Navigation Links
AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis

that this first AP study for ulcerative colitis revealed our treatment to be clinically active, despite the short seven day treatment period and the severity of the patients' disease. These results are very promising for the future development of AP for ulcerative colitis, where we plan to administer AP treatment for longer periods. Also importantly, results from this trial revealed that the treatment is very well tolerated. This is potentially good news for ulcerative colitis sufferers, who are looking for safe and effective treatment options."

AM-Pharma will continue to study the oral use of AP for ulcerative colitis in a further Phase II clinical study. Once safety and efficacy have been confirmed in a larger group of patients, AM-Pharma intends to license the product to a partner who will take on the late-stage development and worldwide commercialisation of AP.

Notes to editors:

About AM-Pharma www.am-pharma.com AM-Pharma is a biopharmaceutical company focused on the preclinical and clinical development of novel compounds in the field of severe infectious diseases and inflammatory diseases. All its products are based on endogenous molecules which have been optimised to combat disease.

AM-Pharma is currently conducting Phase II clinical trials for two products; Alkaline Phosphatase for sepsis, acute renal failure and ulcerative colitis; and Anti-microbial Peptide hLF1-11 for the prevention of infections in hemopoietic stem cell transplant patients.

AM-Pharma is based in Bunnik, The Netherlands with a staff of 20. The company is financed by, amongst others, Forbion Capital Partners, Inventages Venture Capital and Theratase plc. Once product safety and efficacy have been established, AM-Pharma will look for world-wide development and marketing partners for its products.

About Alkaline Phosphatase (AP)

The endogenous enzyme Alkaline Phosphatase is expr
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. AM-Pharma Announces Positive Results of a Phase IIa Clinical Trial with Alkaline Phosphatase in Acute Renal Failure
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:7/30/2015)... July 30, 2015  Medimetriks Pharmaceuticals, Inc. announced ... Phase III clinical study for Ozenoxacin, a novel ... owns the exclusive U.S. rights to Ozenoxacin 1% ... at 44 centers with an emphasis on U.S. ... 2 months and older with a clinical diagnosis ...
(Date:7/30/2015)... SAN FRANCISCO , July 30, 2015 ... devices market is expected to reach USD 23.01 ... Grand View Research, Inc. Growing base of geriatric population, ... and infections, and rising level of awareness among target ... impact rendering drivers over the forecast period. According to ...
(Date:7/30/2015)... , July 30, 2015  NanoSmart Pharmaceuticals, Inc., ... platforms, has received Orphan Drug Designation from the ... drug product that uses NanoSmart,s proprietary drug delivery ... dactinomycin for the treatment of Ewing,s sarcoma, a ... granted NanoSmart,s Orphan Drug Designation on the basis ...
Breaking Medicine Technology:Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 2ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 4ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 5NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2
... of Iomai Adjuvant ... Patch -, ... announced that it has begun dosing in a Phase 1/2,study that will ... in combination with an injected,H5N1 influenza vaccine. The Iomai patch, which ...
... Biopure Corporation,(Nasdaq: BPUR ) today announced that it ... use protocol submitted by the company in July. At,the ... for a Phase,2 randomized trial for the treatment of ... alloantibody anemia but,excluding sickle cell anemia. Hemopure has been ...
Cached Medicine Technology:Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine 2Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine 3Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine 4Biopure Reports on Meeting with the FDA 2Biopure Reports on Meeting with the FDA 3
(Date:7/30/2015)... ... July 30, 2015 , ... Glidewell Laboratories, industry-leading provider of ... magazine, its multimedia publication focused on implant dentistry, is now available in print ... 6, Issue 2, as well as past issues of the dental laboratory’s quarterly ...
(Date:7/30/2015)... ... July 30, 2015 , ... Western University of Health Sciences faculty, students ... World Games, the largest sports and humanitarian event in the world this year and ... World Games, held July 25 through August 2, 2015, benefited from the participation of ...
(Date:7/30/2015)... , ... July 30, 2015 , ... On July 23rd ... billion in taxpayer money to fund the state’s large prison system, which has amassed ... the highest rates of incarceration. In light of President Obama’s recent reduction of non ...
(Date:7/30/2015)... ... July 30, 2015 , ... Quintessa Medical Spa is happy to offer patients ... designed specifically for the elimination of excess tissue under the chin, referred to ... state of Wisconsin to offer this innovative treatment. , Developed by Kythera Biopharmaceuticals, Kybella ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... Gummy ... including lip lowering, gum contouring and surgery, as well as the patented gum depigmentation ... that has made him popular with many patients from around the world. , “Like ...
Breaking Medicine News(10 mins):Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 2Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 4Health News:WesternU Makes Big Impact at Special Olympics 2Health News:WesternU Makes Big Impact at Special Olympics 3Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 2Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 3Health News:Quintessa MedSpa Offers Nonsurgical Double-chin Elimination 2Health News:Gummy Smile Dentist, Alex Farnoosh DMD, is Now Offering Comprehensive Treatment Options for Gummy Smiles 2
... Researchers at the Food Technology Plant Special Research Centre ... celiac disease// otherwise called as gluten sensitive enteropathy. This ... known to have enhanced nutritive value and increased shelf ... of gluten, forcing sufferers to follow a strictly gluten-free ...
... plenty of good reasons, the term “trans fat” leaves ... Typically, trans fatty acids are bad for health, but// ... have coaxed out significant health benefits by juggling the ... professor of food science, and graduate student Vishal Jain ...
... today urged Australians to spare a thought this week for ... time of year for most people means joyful gatherings with ... and despair,' Dr Yong said. ,'The social circuit, ... can cause depression for those who are socially isolated. ...
... obstinate, as scientists have discovered, as they portray a ... extremely// difficult to annihilate. In fact radiation could even ... from the University of California, Los Angeles, who are ... cells that get radiation resistant and render breast cancer ...
... producing cane sugar with lower glycaemic index (GI) that it ... ranking system for carbohydrates based on their immediate effect on ... risk of diabetes because they trigger rapid increases in blood ... ,The sugar, developed by firm 'Horizon Science of ...
... 'DNA-diets', advertised extensively on the internet, making tall claims of ... ,A study, spearheaded by researchers at the Economic and Social ... University of Exeter, is the first study of its kind ... diets are also called 'nutrigenomic' diets that are customized diet ...
Cached Medicine News:Health News:Gluten Free Bread: Boon for Celiac Disease 2Health News:Healthy Potato Chips: A Trans Fat Oil With Health Benefits 2
... SPRING-GRIP™ single use nonconductive anchoring devices are ... mm and 12 mm sizes for use ... mm, 5 mm-10 mm, 5 mm-11 mm, ... sizes for use with the VERSAPORT™, SURGISPIKE™, ...
... line of Surgical Access ...unlike any trocar ... trocar system is actually four systems in ... flexible and clinically adaptive to all of ... disposability and bladed or dilating tip styles, ...
... FPK01 Thoracic Trocar Pak contains: ... flexible sleeves and (1) 12mm ... ,FPK02 Thoracic Trocar Pak contains: ... flexible sleeves., ,FPK03 Thoracic ...
... of three separate components: an exchange rod, a ... transparent trocar sleeve. The exchange rod is a ... long. The dilating obturator is tapered and threaded ... opening created by the 10/11mm or the 12mm ...
Medicine Products: